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Background: Sustained acting atrial natriuretic peptide (SA-ANP) is a 40 amino acid (AA) peptide consisting of native ANP(1-28) and a 
C-terminal extension of 12 AA. Previous studies suggest SA-ANP possesses greater and sustained biologic actions compared to native ANP. We 
sought to determine the physiologic actions and potential therapeutic applications of SA-ANP in a model of acute hypertension and left ventricular 
dysfunction.
Methods: Integrated physiological studies were performed in a canine model of angiotensin II induced hypertension (20 ng/kg/min continuous 
infusion) before, during, and up to 3 hours following a 45 minute infusion of SA-ANP (30 pmol/kg/min) (n=6) or vehicle (normal saline, n=6). 
Angiotensin infusion significantly increased blood pressure and pulmonary capillary wedge pressure and decreased cardiac output.
Results: In this model of acute angiotensin induced hypertension and left ventricular dysfunction, SA-ANP infusion significantly decreased blood 
pressure and pulmonary capillary wedge pressure. Despite a reduction in blood pressure, SA-ANP enhanced renal function with significant increases 
in glomerular filtration rate, renal blood flow, diuresis, and urinary sodium excretion. These systemic and renal actions of SA-ANP were associated 
with significant increases in both plasma and urinary cGMP. Finally, angiotensin activation of aldosterone was suppressed after SA-ANP infusion.
Conclusions: In an acute model of hypertension and left ventricular dysfunction that SA-ANP reduced blood pressure while enhancing renal blood 
flow, glomerular filtration rate, and sodium/water excretion and thus may serve as a potential therapeutic agent in the treatment of hypertension in 
the setting of left ventricular dysfunction.
